Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Reduced-intensity Conditioning
74%
Overall Survival
36%
Myelodysplastic Syndrome
35%
Hazard Ratio
25%
Confidence Interval
25%
Non-relapse Mortality
24%
Graft-versus-host Disease (GvHD)
22%
Marrow Transplantation
18%
Acute Myeloid Leukemia
18%
Allo-RIC
17%
Risk Factors
17%
Pretransplant
17%
HLA-identical Sibling
17%
High Risk
15%
Unrelated Donor
13%
Multivariate Analysis
13%
Chemotherapy
12%
Inolimomab
10%
Infection-related Mortality
10%
American Society
10%
Transplantation
10%
Hematopoietic SCT
9%
Sirolimus
9%
Hematopoietic Cell Transplantation-specific Comorbidity Index
9%
High-risk Myelodysplastic Syndrome
9%
Steroid-refractory Acute Graft-versus-host Disease
9%
Refractory Acute Graft-versus-host Disease
9%
Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
9%
Human Leukocyte Antigen
9%
Poor Prognosis
9%
Conditioning Regimen
8%
Hematopoietic Stem Cell Transplantation
8%
Cumulative Incidence
8%
Leukemia Patients
8%
Single Institution
7%
Progression-free Survival
7%
Primary Myelodysplastic Syndrome
7%
Post-transplant Lymphoproliferative Disorder
7%
Rituximab
7%
Older Patients
7%
Consecutive Patients
6%
Risk Category
6%
Graft-versus-host Disease Prophylaxis
6%
Mucositis
6%
Predictive Models
6%
Cytarabine
6%
CD34+
6%
Allogeneic PBSCT
6%
Peripheral Blood Stem Cell Transplantation
6%
Medicine and Dentistry
Reduced Intensity Conditioning
69%
Myelodysplastic Syndrome
44%
Hematopoietic Cell
39%
Allogeneic Stem Cell Transplantation
36%
Cell Transplantation
34%
Overall Survival
31%
Transplantation
24%
Hazard Ratio
21%
Allogeneic Hematopoietic Stem Cell Transplantation
21%
Graft Versus Host Reaction
20%
Acute Myeloid Leukemia
20%
Diseases
18%
Infection
15%
Acute Graft Versus Host Disease
15%
Conditioning
14%
Human Leukocyte Antigen
12%
Chemotherapy
12%
Comorbidity
11%
Multivariate Analysis
11%
Cumulative Incidence
10%
Scoring System
10%
Stem Cell Therapy
10%
Fludarabine
10%
MNGIE Syndrome
9%
Azacitidine
9%
Rapamycin
9%
Non-Relapse Mortality
9%
Hematopoietic Stem Cell Transplantation
8%
Rituximab
7%
T Cell
7%
Posttransplant Lymphoproliferative Disease
7%
Progression Free Survival
6%
International Prognostic Scoring System
6%
Hematologic Malignancy
6%
High Risk Population
6%
Cytarabine
6%
Cyclosporine
6%
Cytomegalovirus Infection
6%
Prophylaxis
6%
Bone Marrow Transplantation
5%
Inolimomab
5%
Epstein Barr Virus
5%
Cancer
5%
Thrombocytopenia
5%
Methotrexate
5%
Mycophenolate Mofetil
5%
Tacrolimus
5%
Acute Lymphoblastic Leukemia
5%
